These psychedelics may soon be “legal”
While both MDMA and psilocybin show promise for hard-to-treat psychiatric disorders, it’s important to keep in mind that the conditions in these studies were strictly controlled and the patients meticulously monitored during treatment.
Once approved, MAPS says the drug will be administered in an inpatient setting at DEA-certified clinics by licensed therapists who have been specifically trained to conduct MDMA-assisted therapy for the treatment of PTSD. It will not be available as a prescription at local pharmacies, the organization says … The wave of research on psilocybin has broadened into its effect on alcoholism, a significant problem in the U.S. Nearly 13 percent of American adults have an alcohol use disorder, and 88,000 Americans die of alcohol-related causes annually—making it the third leading cause of preventable death, according to the National Institute on Alcohol Abuse and Alcoholism. Researchers at NYU recently began a phase II trial of 180 participants to evaluate the effect of psilocybin, with accompanying behavioral therapy, on alcohol dependence, following a positive preliminary study published in The Journal of Psychopharmacology in 2015. The new trial is expected to conclude in 2020 and, if successful, could lead to a larger study designed for FDA approval—following a similar trajectory to the MDMA trial process. Sponsors and collaborators are either academic or nonprofit and include the University of New Mexico and The Heffter Institute. Researchers are also looking into the use of psilocybin in combination with cognitive behavioral therapy for smoking cessation, and possibly as part of treatment for other substance-abuse disorders.